Serina Therapeutics (SER)
Develops long-acting drug conjugates through its POZ polymer platform.
Something off on this page? Send us feedback.
Develops long-acting drug conjugates using its POZ polymer platform, led by SER-252 for advanced Parkinson's disease. A pre-commercial model centers on research and development, grants, financing, and platform licensing or co-development rather than product sales.
Develops long-acting drug conjugates using POZ, a proprietary polymer platform designed to control drug loading and release. Its lead program, SER-252, pairs POZ with apomorphine for advanced Parkinson's disease and is being evaluated with Enable Injections' enFuse wearable subcutaneous delivery system. SER-270 applies the platform to a VMAT2 inhibitor for tardive dyskinesia, while SER-214 remains a potential partnering asset.
Runs a pre-commercial research-and-development model supported by grants, financing, and platform licensing or co-development rather than product sales. Pfizer holds a non-exclusive license to specified POZ intellectual property in an LNP delivery field; other applications include small molecules and antibody-drug conjugates.
Clinical work spans sites in the United States and Australia and relies on contract organizations, manufacturing partners, and the enFuse relationship. Reports a single segment: research and development of its POZ platform.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $23.0M · Total debt $3.2M · Total assets $25.8M · Shareholders' equity $18.7M
- Revenue
- $0
- Operating income
- −$6.8M
- Net income
- −$6.4M
No dividends on record.
| Institutions25 holders · as of Mar 31, 2026 | 9.82% | 1.47M shares | |
| Otherremainder | 90.18% | 13.53M shares |
15.00M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (25.40M in the company's Sep 3, 2026 report, 15.00M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Sio Capital Management, LLCInstitution | 6.67% | 1.00M | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 1.06% | 159,136 | 13Fas of Mar 31, 2026 |
Waverly Advisors, LLCInstitution | 0.45% | 67,492 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.43% | 64,973 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 0.39% | 58,264 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Supernus Pharmaceuticals
Closest rival in continuous apomorphine delivery for advanced Parkinson's.
- AbbVie
Rival in continuous subcutaneous therapy for advanced Parkinson's.
- Neurocrine Biosciences
Established VMAT2 franchise in tardive dyskinesia and Huntington's chorea.
- Teva (ADR)
Established VMAT2 therapy in tardive dyskinesia and Huntington's chorea.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Serina Therapeutics | $2.65 | −1.85% | $39.3M | — | — | — | −100.0% |
| Supernus Pharmaceuticals | $43.90 | −0.30% | $2.56B | — | 15.2 | 3.1 | +32.4% |
| AbbVie | $262.35 | +0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Neurocrine Biosciences | $158.51 | +0.47% | $15.87B | 23.1 | 17.3 | 4.7 | +39.5% |
| Teva (ADR) | $37.49 | +0.05% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| Median | 62.5 | 16.2 | 3.9 | +21.3% |